Cytosorbents Corporation ( CTSO) Stock. Should you Buy or Sell? $ 1.73
0.04 (2.26 %)
Cytosorbents Corporation Analysis
Updated on 10-09-2022| Symbol | CTSO |
| Price | $1.73 |
| Beta | 0.362 |
| Volume Avg. | $237.28 thousand |
| Market Cap | $75.39 M |
| 52 Week Range | $1.65 - $8.9 |
Cytosorbents Corporation opened the day at $1.73 which is +'2.26 % on yesterday's close. Cytosorbents Corporation has a 52 week high of $8.9 and 52 week low of $1.65, which is a difference of $7.25. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $75.39 M and total net profit is $43165527 which means the company is trading at 1.75 times profit to market capitalization. Theoretically, if you were to buy Cytosorbents Corporation for $75.39 M, it would take 15 years to get your money back. Cytosorbents Corporation are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Cytosorbents Corporation Stock Forecast - Is Cytosorbents Corporation a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -2.119 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -2.538 |
Valuing Cytosorbents Corporation
| Price Book Value Ratio | 1.585 | Price To Book Ratio | 1.585 |
| Price To Sales Ratio | 5.378 | Price Earnings Ratio | -2.119 |
How liquid is Cytosorbents Corporation
| Current Ratio | 3.946 |
| Quick Ratio | 3.348 |
Debt
| Debt Ratio | 0.332 | Debt Equity Ratio | 0.497 |
| Long Term Debt To Capitalization | 0.216 | Total Debt To Capitalization | 0.221 |
Latest news about Cytosorbents Corporation
Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Amy Vogel – Investor Relations Phillip Chan – Chief Executive Officer Kathleen Bloch – Chief Financial Officer Christian Steiner – Executive Vice President-Sales and Marketing and Managing Director-Cytosorbents Europe GmbH Christopher Cramer – Vice President-Business Development Efthymios Deliargyris – Chief Medical Officer Vincent Capponi – Chief Operating Officer and President Mike Gibson – Principal Co-Investigator-STAR-T Conference Call Participants Zach Weiner – Jefferies Brian Kennedy – Cowen Sean Lee – H.C. Wainwright Operator Good afternoon, and welcome to Cytosorbents Second Quarter 2022 Financial and Operating Results Conference Call.
PRINCETON, N.J. , July 25, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2022 operating and financial results after the market close on August 2 nd, 2022.
The Nasdaq Composite dropped by more than 400 points on Friday. Investors, meanwhile, focused on some notable insider trades.
Insiders are buying these penny stocks. The post 10 Top Penny Stocks To Buy In June According To These Insiders Part 1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Terri Anne Powers - Vice President, Investor Relations & Corporate Communications Phillip Chan - Chief Executive Officer Vincent Capponi - President & Chief Operating Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - Executive Vice President, Sales & Marketing and Managing Director of Cytosorbents Europe Christopher Cramer - Vice President, Business Development Efthymios Deliargyris - Chief Medical Officer Conference Call Participants Frank Pinal - Jefferies Justin Walsh - B. Riley Securities Zach Weiner - Jefferies Priya Sachdeva - SVB Operator Good afternoon and welcome to the Cytosorbents Corp.'s First Quarter 2022 Earnings Conference Call.
About Cytosorbents Corporation
Description :
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
